SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Pharmaceutical

SciClone Pharmaceuticals Inc

�� ��

David Wilgus

Peter Shao

Li Mao

���ɣ�Phil�� ��

Cecile Pan

Bokang Zhou

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

��

SciClone Pharmaceuticals Inc

Org chart

Teams

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

Similar companies

��������

SciClone Pharmaceuticals Inc

Org chart

Teams

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

Similar companies

��